Abstract Among the multrple mechanisms postulated for the increased risk of hypertensive left ventrrcular hypertrophy (LVH), coronary hemodynamrc alterations remam a strong possrbrhty Thts study was designed to compare the effects of treatment with an ACE mhlbrtor (enalapnl) and an angrotensm AT, receptor antagonist (losartan) on systemic and coronary hemodynamics and to determine whether the combmatlon of these two renm-angrotensm system (RAS) mhlbrtors would be as or more effectrve m reducing mean arterial pressure (MAP), left ventncular (LV) mass, and tmprovmg coronary hemodynamtcs than etther regimen alone Thus, 23 week old spontaneously hypertensive rats (SHR) were treated (12 weeks) with tap water (C), enalaprd (30 mg kg-' d-l), losartan (30 mg kg-' d-'), or then combmatron (15 mg kg-' d-') Age-matched Wtstar-Kyoto (WKY) rats served as normotenslve controls After 12 weeks, systemic and coronary hemodynamtcs were determmed (15 pm radrolabeled microspheres) at baseline, durmg maximal treadmill exerctse, and durmg maximal ddatton (drpyndamole) Enalapnl and losartan equally reduced MAP and LV mass m association with a decreased total peripheral resistance The RAS combmanon reduced MAP and LV mass more than either drug alone Resting cardiac index and coronary blood flow (CBF) per umt of LV mass did not differ among the groups. Although enalaprd dtd not improve coronary flow reserve (CFR), tt drmunshed muumal coronary vascular resistance (MCVR), losartan improved both However, the combmatton was more effective than either agent alone, reaching values close to normotenslve WKY controls In concluslon, these data demonstrated sigmficantly impaired maximal CBF, CFR, and MCVR m untreated SHR, but losartan alone and m combmatron with enalapnl improved systemic and coronary hemodynamtcs more than enalaprtl alone (Hypertension. 1997;29[part 21519-524.) Key Words l left ventricular hypertrophy [reversal] l angrotensm II [antagonism and mhtbrtron] l drug synergism l losartan l enalapnl l coronary circulation l spontaneously hypertensive rats L eft ventricular hypertrophy resultmg from hypertension IS an independent rusk factor for premature cardtovascular morbidity and mortality, t-3 although LVH reversal has not ye@een shown to reduce that risk 4 LVH has been associated with impaired coronary hemodynamrcs m expenmental animal+ and patients 7-9 Among the postulated mechanisms offered to explain the increased risk are altered coronary hemodynamrcs, including decreased CBF and CFR, increased resting and MCVR, and altered vrscostty; cardtac arrhythmias, cardiac failure, and accelerated atherosclerosis of epicardial arteries. 10 Current goals of antthypertenstve therapy have been directed toward optimal control of arterial pressure, although reversal of LVH and rmprovement of the compromtsed coronary hemodynamrcs are the SubJect of intense investrgatron directed toward reducing LVH risk.4 Accordmgly, this study was designed to determine whether treatment wrth an ACE inhibitor (enalapnl), an AT, receptor antagomst (losartan), or then combmatton improved coronary hemodynamtcs m assoctatron with reduced LV mass
L eft ventricular hypertrophy resultmg from hypertension IS an independent rusk factor for premature cardtovascular morbidity and mortality, t-3 although LVH reversal has not ye@een shown to reduce that risk 4 LVH has been associated with impaired coronary hemodynamrcs m expenmental animal+ and patients 7-9 Among the postulated mechanisms offered to explain the increased risk are altered coronary hemodynamrcs, including decreased CBF and CFR, increased resting and MCVR, and altered vrscostty; cardtac arrhythmias, cardiac failure, and accelerated atherosclerosis of epicardial arteries. 10 Current goals of antthypertenstve therapy have been directed toward optimal control of arterial pressure, although reversal of LVH and rmprovement of the compromtsed coronary hemodynamrcs are the SubJect of intense investrgatron directed toward reducing LVH risk.4 Accordmgly, this study was designed to determine whether treatment wrth an ACE inhibitor (enalapnl), an AT, receptor antagomst (losartan), or then combmatton improved coronary hemodynamtcs m assoctatron with reduced LV mass
Procedures

Methods
Male SHR and normotenstve WKY rats were obtained from Charles River Breeding Laboratories Inc (Wdmmgton, Mass) at 14 weeks of age and were mamtamed thereafter m accordance with our mstttutlonal animal care committee gutdelmes after prior From Hypettenslon Research Laboratones, Alton Ochsner Medtcal Foundatton, New Orleans, La
Correspondence to Edward D Frohhch, MD, Vice President for Academtc Affaus, Alton Ochsner Medtcal Foundanon, 1516 Jefferson Hwy, New Orleans, LA 70121 0 1997 Amencan Heart Association, Inc approval of the experimental protocol They were housed m temperature-controlled rooms on a 12-hour hght/dark cycle and were fed usual rat chow and water ad hbttum At 23 weeks of age, the rats were randomly assigned to one of five groups of 16 rats each untreated normotensrve WKY-C (tap water), untreated SHR-C (tap water), SHR-E (30 mgskg-' d-' by gavage), SHR-L (30 mg kg-' d-' by gavage), and SHR-E&L (5 mg kg-' d-' of each agent by gavage). The rats followed then respective treatments for 12 weeks. All rats were tramed to run on a motordriven treadmill (Columbus Instruments) at speeds rangmg from 0.5 to 1 0 m/mm, 0% grade, for =5 mm/d for 2 to 3 days a week during the final 2 weeks of the protocol to familiarize them with treadmill running 11 At 35 weeks of age, the rats wete instrumented for determtnation of systemtc and coronary hemodynamrcs using the reference standard microsphere method as described prevtously by our laboratory. 12.13 Thus, under ketamme (10 mg/kg) and acepromazme (50 mg/kg) anesthesia, they were cannulated with three polyethylene catheters (PE-50) one inserted mto the LV (vta right carotid artery) for qection of mlcrospheres, a second inserted mto the caudal (tad) artery for artenal pressure measurement and for reference sample withdrawal, and a third inserted into aJugular vem for dlpyndamole mfuston These catheters were extenonzed at the nape of the neck and filled with heparunzed salute solution (200 LJ/mL), and the rats were returned to then nonrestrlctrve plastic cages to recover tully over at least 3 hours Radtolabeled (57Co, "'Sn, and 46Sc) mtcrospheres (DuPont) of 15-pm diameter were used for each blood flow measurement Thus, 100 000 mrcrospheres, suspended m 0 045 mL saline contammg <0 01% Tween 80, were infused mto the LV over 5 seconds, followed by 0 5 mL warm saline flush qection over 15 seconds Before mfuslon, the microsphere suspension was mixed thoroughly on a touch mixer (Vortex) for 1 to 2 mmutes, during the mfuston, the Sdasttc tube contaunng the microsphere suspension was constantly tapped to ensure even dtstnbutlon The reference sample was withdrawn at a rate of 0 45 mL/mm over 60 seconds (mcludmg 10 seconds before and 20 seconds after qection) Efficacy of microsphere-blood mtxmg was assessed by comparing Hypertension Vol29, No 1, Part 2 January 1997
Selected Abbreviations and Acronyms CBF = coronary blood flow CFR = coronary flow reserve CO = cardiac output CVR = coronary vascular resistance CVRI = coronary vascular resistance mdex LV = left ventricular/ventricle LVH = LV hypertrophy MAP = mean arterial pressure MCVR = minimal coronary vascular resistance RV = right ventncular/ventncle SHR = spontaneously hypertensive rats SHR-C = SHR controls SHR-E = enalapril-treated controls SHR-E&L = combmatlon-treated controls SHR-L = losartan-treated controls TPRI = total peripheral resistance index WKY = Wlstar-Kyoto WKY-C = WKY controls blood flows to the right and left ludneys; a difference of ~15% for these two flows was considered unacceptable, and the study was excluded Adequate trapping of microspheres was evaluated by counting lung radioactivity, and if the percentage of blood flow to the lungs was 5% or greater (excessive AV shunt), the rat was also ellmmated from the study. 14~5 At the end of the study, the rat was lulled with an overdose of pentobarbital, and the heart was removed lmmedlately After the atria was discarded, the free wall of the RV was carefully removed, leaving the LV free wall and septum as total LV weight Further, the LV was dlssected Into two segments, subepicardmm and subendocardmm, to assess regional myocardlal perfusion These segments were carefully cleaned, blotted dry, and weIghed on a preclslon grammatic balance Ventricular weights were normalized for body weight and expressed as RV and LV mass (mg/g) A fixed segment (4 5 cm) of the descending aorta, starting at a point distal to the subclavlan artery, was removed, welghed, and expressed as aortlc mass mdex (mg mm-' g-') Tissue samples, as well as the blood reference sample, were placed m plastic scmtlllation vials and counted for 15 minutes m a deep-well gamma scmtdlation spectrometer (Packard) using a multichannel analyzer CO and CBF were calculated from the counts per minute and the sample wet weights accordmg to standard procedures after appropnate corrections for decay and background Spdlover correction between channels was achieved using matrix mversion software (Compusphere, Packard) Thus, CO and the CBF were calculated using these formulas: CO (mL/rnm)=I (cpm)XSR (mL/rnm)iRS (cpm) and CBF (mL/mm)=LV (cpm)XSR (I&/ mm)/RS (cpm), where I 1s total rachoactlvity injected and was calculated as the difference m counts m the tubmg before and after mJe&on of the microspheres, RS 1s counts m the reference blood sample, SR 1s rate of withdrawal from the reference arteries, and LV 1s LV count Cardiac index and TPRI were calculated and expressed as ml/mm/kg and U, respectively CVR was calculated by dividing mean artenal pressure (MAP), recorded Just before each rmcrosphere injection, by its correspondmg CBF The CBF and CVR were normahzed with respect to RV and LV weight (CBF per gram of myocarchum and CVRI) and expressed as mL/ nu/gm and U, respectively A total of 18 rats were discarded from the study because of unsuccessful cannulation, uneven microsphere distribution to both ludneys, or pulmonary AV shuntmg Protocol After full recovery from anesthesia, the rats were studied while unrestrained m a open-top plastic cage. Both the caudal arterial and LV catheters were connected to Gould-Statham pressure transducers (P23D by Statham Instruments) MAP and HR were recorded throughout the study on a multichannel physlograph coupled with a carchotachometer (Sensor Medics R612) Basehne (control) measurements were obtained after 30 minutes of hemodynamic stabdization using a first mIcrosphere ("Co) inJection After these baselme measurements were obtamed, each rat ran on the treadmill starting at a speed of 0 4 m/s that was increased at a rate of 0 15 m/s every minute until exhaustion, mdlcated by mabihty to mamtam a pace with the treadmdl 1113 The second microsphere ('*'Sn) mJec&on was given at the peak of maxlmal exercise Then, after full recovery from exercise (60 minutes), maximal coronary vasodllatation was produced by dlpyndamole, admmistered (4 mg kg-' mm-' IV for 10 mmutes) using a Harvard mfusionlwithdrawal pump (Harvard Apparatus) 16 Maximal CBF then was determined by mJectmg the third radlonuchde microsphere (46Sc) while the dlpyndamole was Infused contmually for 1 to 2 minutes after the mlcrospheres were injected
Statistical Analysis
All results are expressed as mean+-SEM The pared Student's t test was used for group comparisons (basehne versus tread&l or baselme versus dipyndamole) Single-factor ANOVA was camed out to assess differences between treatment groups 17 The mean change from baselme (with treadmdl or dlpyndamole) IS expressed as a CVR and was tested for statistical sigrnficance usmg ANCOVA with treatment group as a factor and the baseline as a covanate 18 When the F statlshc from ANOVA or ANCOVA was sigmficant, panwise compmsons were made using the Student-Newman-Keuls post-hoc test to adjust for multiphcity of testing 19 Correlation coefficients were computed using a least-squares linear regression analysis.17 Data analysis and calculations were accomplished by JMP version 3 1 5 statistical software (SAS Institute Inc) The level of slgmficance was defined at an (YS 05 Results Body, Aortic, and Cardiac Mass Body weight was significantly less m untreated SHR than normotenslve WKY-C (P< OS), however, there were no differences among the treated SHR groups with respect to the untreated SHR (Table 1 ) There were no differences m RV mass among the WKY and SHR untreated groups, however, it was significantly reduced m the three treated groups (Table 1) . Aort~c mass mdex was slgmficantly lower m the WKY-C than the SHR-C, and all treatments diminished aortlc mass index m SHR groups (without dlfferences between treatment groups) LV mass was markedly increased in untreated SHR rats (compared with WKY (P-C 01) and all three SHR treatment groups (P-C 01, each group) The combmation therapy reduced LV mass (by 21%) more than enalapnl (17%, P< 05) or losartan (15%, P< 01) alone LV mass and MAP of the SHR control and treatment groups were directly correlated (r= 670, P< 01)
Systemic Hemodynamics MAP and TPRI were slgmficantly increased m the SHR-C (148t5 versus 98?6 mm Hg, P<.Ol, and 0,385+0 032 versus 0 240~0 015 LJ, P<.Ol, respectively) with respect to the WKY-C Moreover, MAP was reduced by enalaprll (20%, P< Ol), losartan (20%, P<.Ol), and then combmatlon (34%, P< 01); the latter was reduced more than either drug alone (P< 05). This MAP reduction was achieved through a significant decrease in TPRI, there were no differences between groups in heart rate or cardiac index (Table 2) .
Coronary Hemodynamics
Restmg CBF (per umt of RV and LV mass) did not differ among the various SHR groups Because MAP was lower m WKY-C and was slgmficantly reduced by treatment in the SHR groups, CVRI was also reduced m these groups. However, only the untreated WKY and the comdynamics, although exercise was far less effective than bination treatment were significantly lower than the pharmacological intervention (Table 4 ) Finally, LV CFR SHR-C (both P< 01) The distribution of CBF in subenwith dlpyndamole was inversely related to basal MAP docardlal and subepicardial layers (expressed as a ratio) and LV mass (r=-0 40, P< 01, and r=-.43, P<.Ol, showed no differences among the groups (Table 2) respectively)
Exercise and Dipyridamole Interventions Discussion MAP was reduced m all groups except SHR-C by dlpyridamole (P<.Ol) and with treadmill exercise (Table 3) . Treadmill exercise induced a moderate but significant fall m TPRI that was associated with a slightly faster heart rate in all treated groups; however, only the group recelvmg both enalaprll and losartan achieved srgmficant mcreases m both heart rate and cardiac index Dlpyrldamole mfuslon increased LV CBF m all groups (P< 01) except the SHR-C CBF reserve (defined as the difference between maximal CBF achieved with dipyndamole and the basal CBF) was srgmficantly greater with SHR-L and SHR-E&L (3 2320.68 mL mm-'*g-l, P< 05, and 3.8020.45 mL mu-' g-', P< 01, respectively) than m the SHR-C (1.4720.39 mL*mn-' g-') CVRI was reduced m all groups by dlpyridamole (P< 01 for each); however, the CVR (expressed as the ratio between MCVR and CVRI at baseline) was significantly reduced by SHR-L and SHR-E&L (0 55+0 06, P< 05, and 0 52?004, P< 01, respectively) in comparison with the SHR-C (0 67~0 05) Minimal CVR, achieved after maximal dilation with dlpyridamole, was reduced m all three treatment groups as well as wtth the WKY-C (P<.Ol for each) Durmg treadmill exercise, there was a similar trend m coronary hemo-
The results of this study demonstrated that long-term AT, receptor blockade alone or m combmatron with ACE mhrbmon was effective in improving coronary hemodynamlcs associated with reduction m cardiac mass related to LVH Three lines of evidence support this conclusion (1) enalapril and losartan equally reduced MAP and LV mass; (2) the combmation of enalaprtl and losartan (m half-doses of each when used alone) reduced pressure and LV mass more than either drug administered alone, and (3) although enalapnl had no effect on coronary hemodynamics, only losartan or the combmation was more effective m normahzmg coronary hemodynamics (to a values closer to that of normotensive WKY) ACE mhlbitors as well as AT, receptor antagonists are extremely effective in reducing arterial pressure; however, it is not clear why the simultaneous use of both agents was more effective than either agent when used alone m twice the dose of each. Furthermore, this greater effect of the combined therapy was reduced LV mass more than erther drug when used alone. Prior studies from our and other laboratories using ACE mhlbttors20-24 demonstrated reductton of cardiac mass even when arterial pressure was suboptimally reduced, suggesting nonhemodynamtc effects of mhlbltlon of the generation of anglotensm 112021,*5-*7 or an addltlonal effect of kmms associated with ACE mhlbltlon.*s-32 However, the latter mechanism seems less likely to be operative m the present study since losartan was at least equally as effective or more effective than enalaprll when either was used alone. Supportmg the pnmary hemodynamic effect of losartan m reducing LV mass (as opposed to a nonhemodynamic action) are the findings that AT2 receptors m contrast to the ATI receptors mediate the mltogemc effects of anglotensm II 3334 And further support of this lme of reasoning 1s the highly positive correlation that we demonstrated between LV mass and MAP (r=.67, P< Ol), although nonhemodynamlc factors may still participate. Thus, enalaprll and losartan equally reduced RV mass, although the combmatlon treatment was even more effective (Table 1) This reduction m overall cardiac mass may also be related to a decrease in LV and RV wall collagen content, and while this was not determined m this study, we did show m earlier work that ACE mhlbltlon did in fact diminish RV as well as LV collagen 35, 36 The present study also demonstrated that associated with the reduction m MAP and LV mass, losartan Improved coronary hemodynamlcs, although the combmatlon with enalaprll was even more effective As already stated, hypertensive LVH 1s associated with impaired coronary hemodynamlcs, manifested by reduced CBF, reduced CFR, elevated MCVR, and abnormal subendocardlal autoregulatlon S-9 Reduced CFR m LVH has been attributed to structural alterations of the coronary reslstance vessels (vascular component) manifested by a reduction m reduced arterial vasculanty, capillary density, and decreased total cross-sectional area of resistance vessels 37-41 The myocardial component m LVH may also contribute to an extravascular component of the increased CVR that 1s manifested by forces related to myocardlal contraction and relaxation and by mterstltlal and penvascular myocardlal fibrosis 41 4* In addition, attenuation of endothehally mediated control of CVR may also exist Recent studies have demonstrated impaired endothehally dependent coronary vasodllatatlon m response to acetylcholine in hypertensive patlents,43-45 although enhanced activity of endothehum-derived vasoconstnctmg factor may also be an operating mechanism 46 Additionally, several reports have suggested that abnormalities m coronary circulation persist even after LVH reversal and MAP reduction, suggesting a dlssoclatlon between LV mass and coronary vessel abnormahtles m response to antihypertenslve treatment 214748 In support of this thesis 1s a recent study from our laboratory that was conducted with the same protocol used m the present study In that study, we demonstrated that losartan administered for only 3 weeks did not demonstrate a slgmficant lmprovement m overall coronary hemodynamlcs, although the reductions in MAP (23%) and LV mass (19%) were comparable to the present study 13 Thus, the results of the present study indicate that more than 3 weeks of treatment was necessary to improve all coronary hemodynamlcs and indexes (Table 4) , a finding that may explain negatlve results m short-term trials. On the other hand, we deliberately used a 3-week treatment period m our earlier studies to dlssoclate hemodynamic from nonhemodynarmc effects produced by antlhypertenslve therapy.*@22146 Thus, the present findings also support the hypothesis that angiotensm II, through its effects on AT, receptors, may participate importantly m reducing the CBF reserve associated with LVH However, by adding enalapnl to the losartan (even m half doses of each), the coronary hemodynamic effects were improved further and more slgmficantly This could be explained by the dual effects of mhlbltmg the remn-anglotensm system and the addltlonal effect of ACE mhibltlon on increasing the role of kmms This concept is supported by the finding that losartan, after 12 weeks of treatment, normalized MAP, reduced LV mass, and improved coronary hemodynamlcs, although not to the extent achieved m combmatlon with enalaprll Finally, it 1s important to recognize that despite the controlled MAP, reduction m LV mass, and improved coronary hemodynamlcs associated with AT, receptor antagonism, reduction m cardiac risk was not a feature of the present experimental design Acknowledgments 
